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Abstract
Objectives Carfilzomib is a new agent for the treatment of relapsed and
refractory multiple myeloma (MM). This article presents a comprehensive
overview of the pharmacokinetics, pharmacodynamics, dosing schedule, safety,
efficacy, preparation and administration of carfilzomib, and its role in treating
MM patients.
Key findings Carfilzomib is a selective proteasome inhibitor that differs structur-
ally and mechanistically from bortezomib. In patients’ whole-blood and
peripheral-blood mononuclear cells, carfilzomib inhibited proteasomal and
immunoproteasomal activity by 70–80%. Approved carfilzomib dosing is based
on body surface area, and is given on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle
(20 mg/m2 in cycle 1; 27 mg/m2 in cycle 2+). Premedication with dexamethasone
and adequate hydration are recommended to reduce the risk of adverse events.
The median t1/2 of carfilzomib is short (0.29–0.48 h), with no accumulation
detected between doses. In clinical studies in relapsed and refractory MM. and in
combinations in newly diagnosed MM, single-agent carfilzomib demonstrated
significant durable activity, good tolerability and a favourable safety profile, sup-
porting its extended use.
Conclusions Carfilzomib represents an important addition to the treatment
armamentarium for patients with relapsed and/or refractory MM, and studies are
underway evaluating the role of single-agent carfilzomib in additional clinical set-
tings as well as in different combinations.
Introduction
Multiple myeloma (MM) is a malignant, progressive B-cell
tumour characterized by overproduction of monoclonal
immunoglobulin, osteolytic bone lesions, renal dysfunction
and immunodeficiency.[1] According to estimates from the
American Cancer Society, 22 350 new cases will be diag-
nosed and 10 710 Americans will die from MM in 2013.[2]
MM will represent nearly 15% of new haematologic malig-
nancies diagnosed in 2013.[2] The incidence of MM is
slightly greater in men than in women and ~2-fold greater
in African Americans than in Caucasians.[1,3] In general MM
is a disease of older individuals,[3] with a median age at
diagnosis of 69 years.[1,4–6] The majority of patients with
MM present with bone pain or fractures of unknown aeti-
ology, renal failure, recurrent infections,[6] anaemia and
fatigue.[5]
Over the last decade, the median overall survival (OS)
following treatment for patients with MM has ranged from
4.4 to 7.1 years,[6] and nearly all patients experience eventual
relapse and progression.[7] Therapeutic options for patients
with advanced stage disease, including those relapsed after
multiple prior lines of therapy and those with refractory
disease, are limited, often including experimental agents
and three- and four-drug combinations. For patients with
relapsed or progressive disease, National Comprehensive
Cancer Network (NCCN) guidelines recommend trans-
plantation (in eligible patients), or salvage therapy on or off
clinical trials.[8] However, the majority of the preferred regi-
mens for salvage treatment are limited by drug toxicity and
transient responses.
Carfilzomib (Kyprolis™, Onyx Pharmaceuticals, South
San Francisco, CA) is a selective proteasome inhibitor (PI)
that is US Food and Drug Administration (FDA) approved
as single-agent treatment for relapsed or refractory multiple
myeloma (RRMM).[9] It differs structurally and mechanisti-
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cally from bortezomib. It is a tetrapeptide bearing an epox-
yketone moiety (Figure 1) and functions by irreversibly
inhibiting chymotrypsin-like (CT-L) activity of the protea-
some, thereby eliciting more sustained inhibition than the
reversible PI, bortezomib and greater target specificity,
which may explain the ability of carfilzomib to overcome
resistance to bortezomib both in vitro and in vivo. Carfil-
zomib has been evaluated in clinical studies in patients with
RRMM, and NCCN currently lists it as a preferred regimen
in this population. Carfilzomib has also been studied in the
frontline setting. The goal of this article is to present phar-
macists with a complete overview of the pharmacokinetics
(PK), pharmacodynamics (PD), dosing schedule, safety,
efficacy, preparation and administration guidelines of the
drug.
Pharmacology
Carfilzomib is an analogue of epoxomicin and eponemycin,
related natural products initially shown to inhibit tumours
in animals and later to specifically inhibit the CT-L activity
of the 20S proteasome.[10–14] It is structurally and mechanis-
tically distinct from the dipeptide boronic acid PI bort-
ezomib, which forms a slowly reversible bond with the
proteasome’s catalytic b5 subunit.[15] In contrast to bort-
ezomib, carfilzomib forms an irreversible dual covalent
bond with the catalytic b5 subunit of the proteasome and
with the analogous subunit b5i (LMP7) of the immuno-
proteasome.[16] At therapeutic concentrations, carfilzomib
shows primary selectivity for CT-L activity of the protea-
some and is equipotent to bortezomib,[17] but displays little
activity against the trypsin-like or caspase-like activities of
the proteasome.[17] The selectivity coupled with the irrevers-
ible nature of the inhibition gives carfilzomib a potential
advantage both in efficacy and tolerability over bortezomib.
In preclinical models of MM, inhibition of the protea-
some and the immunoproteasome by carfilzomib in cell
lines and primary cells resulted in dose- and time-
dependent inhibition of proliferation, ultimately leading to
apoptosis.[18] Carfilzomib had greater specificity than bort-
ezomib in these models and also showed significantly less
neurotoxicity and neurodegeneration.[15] Carfilzomib also
overcame resistance to bortezomib and other conventional
agents, and acted synergistically with dexamethasone.[18]
Pharmacokinetics/Pharmacodynamics
Carfilzomib is rapidly and extensively metabolized to inac-
tive metabolites.[16] Cytochrome P450 pathways play only a
minor role in carfilzomib metabolism.[19] Plasma clearance
rates exceed hepatic blood flow rates,[20,21] suggesting a sig-
nificant contribution of extrahepatic mechanisms to elimi-
nation.[16,17] There has been no apparent effect of renal
dysfunction on carfilzomib PK noted to date.[22]
The PK profile of carfilzomib was evaluated in patients
with MM at doses of 11, 15, 20 and 27 mg/m2 (Table 1).[21,23]
Carfilzomib concentrations declined rapidly in a biphasic
manner, and the majority of the drug was eliminated from
the plasma compartment within 30 min.[21–23] The t1/2 of car-
filzomib was short, with a median of 0.29–0.48 h, and accu-
mulation of carfilzomib was not detected.[21,22] This rapid
clearance may explain the favourable safety profile of the
drug.
Area under the curve (AUC) and maximum concentra-
tion (Cmax) both increased in non-dose-dependent fashion
with increasing carfilzomib doses. The volume of distribu-
tion at steady state (Vss) was large and quite variable across
dose levels, suggesting wide tissue distribution.[21,23]
Repeated administration did not appear to alter carfilzomib
exposure, although PK parameters showed a large degree of
interpatient variability.[21,22]
In whole-blood and peripheral-blood mononuclear cells
(PBMCs) from patients with MM, carfilzomib inhibited the
CT-L activity of both the proteasome and the immunopro-
teasome by 70–80%,[17,18] and at 27 mg/m2 ~90% inhibition
has been seen.[23] Cumulative inhibition of CT-L activity
was observed with repeat dosing.[18] Prolonged inhibition is
suggested by the minimal proteasome activity observed on
day 2 of the first cycle.[23] Progressive recovery of activity has
been demonstrated in whole blood and PBMCs within 24,
72 and 168 h,[15,17,18,21] with complete recovery seen at cycle 2
following a 12-day rest period.[23]
Drug interactions
A single drug interaction study was conducted in patients
with solid tumours to determine whether carfilzomib
administration would alter the PK of midazolam, a CYP3A
substrate, following reductions of CYP3A and 1A2 in
vitro.[19] In both a single and repeat dose evaluations, carfil-
zomib did not affect the PK of midazolam, and there were
no safety signals indicative of drug interactions.[19]
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Figure 1 Structure of carfilzomib. Carfilzomib consists of a tetrapep-
tide backbone with an active epoxyketone moiety or ‘warhead’ that is
reactive with the N-terminal threonine active sites of the proteasome.
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In clinical trials conducted to date, there have been no
restrictions on concomitant medications, including cyto-
chrome P450 substrates, inducers, or inhibitors.[9,24] Based
on the metabolic pathways for carfilzomib and the results of
clinical trials to date, significant drug–drug interactions are
not predicted. Continued clinical experience will serve to
confirm this prediction.
Clinical trials
Dose finding and safety studies
Carfilzomib trials PX-171-001 and PX-171-002 were phase
1 open-label dose-finding studies. Study PX-171-001
enrolled 29 patients with relapsed or refractory haemato-
logic malignancies after two or more prior therapies
(Table 2).[21] Patients received carfilzomib at doses up to
20 mg/m2 IV infusion over 1–2 min on days 1–5 every 14
days until evidence of unacceptable toxicity or progressive
disease. The maximum tolerated dose (MTD) with the 5
consecutive-day dosing schedule was defined at 15 mg/m2.
The most common treatment-emergent events of any
grade were fatigue (48%), nausea (48%) and diarrhoea
(35%). Grade 3 and 4 events were reported at 15 and
20 mg/m2 and included thrombocytopenia, anaemia,
unspecified pain, increased aspartate aminotransferase,
febrile neutropenia, neutropenia, chills and dyspnea. Grade
1 and 2 hypoesthesias and paresthesias were reported,
but Grade 3 and 4 peripheral neuropathies (PN) were not.
Of the 28 patients evaluable for response, 4 patients,
all treated at doses of 11 mg/m2 or higher, had
Table 1 Pharmacokinetic parameters of carfilzomib following intravenous administration to patients with haematologic malignancies[21,23]
Carfilzomib dose 11 mg/m2 15 mg/m2 20 mg/m2 27 mg/m2
Study 001 002 001 002 001 002 002
n n = 2 n = 3 n = 5 n = 3 n = 4 n = 8 n = 5
Cmax (ng/ml)
Mean 90.2 505 325.9 143 683.0 528 406
SD 84.9 485 217.8 97 598.5 406 517
t1⁄2 (min)
Mean 25.3 12.9 28.9 13.1 17.1 39.4 26.8
SD 14.1 6.5 37.4 3.6 7.7 28.8 4.7
CL (ml/min)
Mean 5 062 10 437 7 054 30 342 4 127 10 979 74 575
SD 3 958 10 973 7 177 23 890 4 981 5 880 108 935
Vss, L
Mean 42.5 68.4 942 199.1 140 108.4 1 539
SD 65.2 79.5 2 046 116.6 231 71.2 2 862
AUClast (ng·ml/h)
Mean 4 457 4 049a 9 728 1 414a 23 123a 4 911 3 409a
SD 2 520 3 695 10 897 919 17 323 3 495 3 964
aAUClast (ng·min/ml). AUClast, area under curve to last measurable time point (includes C0); CL, systemic clearance; Cmax, maximum plasma concentra-
tion; SD, standard deviation; t1/2, elimination half-life; Vss, volume of distribution at steady state.
Table 2 Dose-finding and safety studies of carfilzomib in relapsed and/or refractory haematologic malignancies: dosing schedule and efficacy
outcomes[21–23,25]
Study Patient population Schedule Carfilzomib dose (mg/m2) ORR (%) CBR (%)
PX-171-001 R-R (MM, WM, NHL, HD) Days 1–5 (14-day cycle) 1.2–20.0 7.1a 14.3a
PX-171-002 (escalation) R-R (MM, NHL, HD) Days 1, 2, 8, 9, 15, 16
(28-day cycle)
1.2–27.0 14.0a 18.6a
PX-171-002 (expansion) R-R (MM, NHL, WM) Days 1, 2, 8, 9, 15, 16
(28-day cycle)
20 (C1)
27 (C2 and higher)
PX-171-005 R-R MM with renal dysfunction Days 1, 2, 8, 9, 15, 16
(28-day cycle)
15, 20 or 27 25.5 31.9
PX-171-007 R-R MM 30 min infusion
Days 1, 2, 8, 9, 15, 16
(28-day cycle)
20 (C1, D1 and 2)
36, 45, 56 or 70
57.1 67.9
aOnly for patients with MM. CBR, clinical benefit response rate; HD, Hodgkin’s disease; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma;
ORR, overall response rate; QD, once daily; R/R, relapsed and refractory; R-R, relapsed or refractory; WM, Waldenström’s macroglobulinemia.
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objective responses (Table 2), including 2 patients with
MM.[21]
PX-171-002 evaluated a patient population similar to 001
and enrolled 48 patients with relapsed or refractory haema-
tologic malignancies after two or more prior therapies
(Table 2).[23] Patients received carfilzomib doses up to
27 mg/m2 IV infusion over 1–2 min on days 1, 2, 8, 9, 15
and 16 of a 28-day cycle until unacceptable toxicity or
disease progression. Single-agent dose escalation (n = 37,
MTD not reached) was followed by a dose expansion
(n = 11) that comprised two cohorts (carfilzomib or
carfilzomib + dexamethasone). During dose expansion, an
escalated regimen was evaluated for a possible decrease in
observed ‘first-dose effects’ associated with tumour lysis
and/or cytokine release. Cycle 1 day 1 and 2 doses were
20 mg/m2, followed by escalation to 27 mg/m2 thereafter.
Dosing in the expansion cohort was well tolerated with the
majority of adverse events (AEs) Grades 1 or 2.
Notable haematologic AEs  Grade 3 were anaemia and
thrombocytopenia. There were no observations of  Grade
3 PN. At doses of 15–27 mg/m2, there was evidence of effi-
cacy among patients with MM and non-Hodgkin’s lym-
phoma (NHL) in 14 of 36 evaluable patients. The results of
this trial demonstrated preliminary safety and efficacy of
the escalated dosing regimen and served as the basis for
subsequent studies.
In the phase 2 PX-171-005 study, single-agent carfilzomib
was evaluated in 50 patients with varying degrees of renal
dysfunction, including 8 patients on chronic dialysis
(Table 2).[22] Carfilzomib was administered by IV infusion
over 2–10 min on days 1, 2, 8, 9, 15 and 16 every 28 days.
Patients received 15 mg/m2 in cycle 1, 20 mg/m2 in cycle 2
and 27 mg/m2 in cycle 3 and beyond. Renal function did not
affect carfilzomib clearance, peak exposure or total expo-
sure, or AE profile.[22] The most common Grade 3/4 AEs
(10%) were anaemia, thrombocytopenia, lymphopenia,
fatigue, pneumonia and pain. Serious AEs (SAEs) occurred
in 33 patients. Partial responses (PR) or better were
reported in 25.5% of patients, and 44.7% had a best
response of (stable disease) SD.[22] The results of this trial
suggest that dosage adjustments are not necessary for
patients with varying degrees of renal function.
Higher doses and an alternative infusion time were evalu-
ated in the phase 1b/2 PX-171-007 study (Table 2). Thirty-
three patients with MM received carfilzomib as a 30-min IV
infusion on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Cycle
1 day 1 and 2 doses were 20 mg/m2, followed by escalation
to 36, 45, 56 or 70 mg/m2.[25] MTD was defined as 56 mg/
m2. Dose-limiting toxicities (DLTs) occurred in 2 patients
treated at 70 mg/m2; both patients continued carfilzomib at
reduced doses. This trial further confirmed the safety and
efficacy of an escalated regimen, while indicating the need
for further study and evaluation of higher doses and alter-
native infusion strategies.
Single-agent studies in RRMM
Two phase 2 studies of single-agent carfilzomib in patients
with RRMM, including those who were heavily pre-treated,
were each analysed by cohorts (Table 3) (PX-171-003 (003-
A0, 003-A1); PX-171-004 (004 bortezomib treated, 004
bortezomib naïve)). In the first cohort of both studies, car-
filzomib was dosed at 20 mg/m2, and in higher cohorts at
20 mg/m2 in cycle 1 followed by 27 mg/m2 in subsequent
cycles.
PX-171-003-A0 and 003-A1 were open-label, multicenter
studies in patients with RRMM following two or more prior
therapies that included bortezomib and an immunomodu-
lator (thalidomide or lenalidomide) and disease refractory
to the last treatment regimen preceding study entry
(Table 3).[26] In 003-A0, patients received carfilzomib
20 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 every 28 days for
up to 12 cycles. Patients enrolled in 003-A1 received carfil-
zomib 20 mg/m2 IV in cycle 1, and then at 27 mg/m2 for up
to 12 cycles (Table 3). Forty-two patients were evaluable for
response in 003-A0, with best overall response (ORR) of
16.7% (Table 3).[26] The median duration of response
(DOR), based on 7 patients with PR, was 7.2 months. The
most common treatment-emergent AEs of any grade were
anaemia (73.9%), fatigue (69.6%), and thrombocytopenia
Table 3 Single-agent phase 2 studies of carfilzomib in relapsed or refractory multiple myeloma: dosing schedule and efficacy outcomes[26–29]
Study
Carfilzomib dose (mg/m2)a
ORR (%) CBR (%)
DOR
(months)
TTP
(months)
PFS
(months)
OS
(months)C1 C2 and beyond
003-A0 (n = 46) 20 20 16.7 23.8 7.2 3.5 3.5 ND
003-A1 (n = 266) 20 27 23.7 37.0 7.8 3.9 3.7 15.6
004 (BTZ-treated) (n = 35) 20 27 17.1 31.4 >10.6 4.6 4.6 29.9b
004 (BTZ-naïve) (n = 129) 20 27 47.6 61.9 >13.1 12.0 11.6 NR
aDays 1, 2, 8, 9, 15, 16 of 28-day cycle. bEstimated. BTZ, bortezomib; CBR, clinical benefit response rate; DOR, duration of response; MM, multiple
myeloma; NR, not reached; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; QD, once daily; R/R, relapsed and refrac-
tory; R-R, relapsed or refractory; TTP, time to progression.
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(50.0%) (Table 4).[26] Common Grade 3/4 AEs were prima-
rily haematologic and included anaemia (37.0%), lympho-
penia (28.3%) and thrombocytopenia (26.1%). PN and
neuropathy-related AEs were generally mild and infrequent
during the study. In 003-A1, 266 patients were evaluable for
safety, while 257 were evaluable for efficacy.[27] Patients had
received a median of five prior lines of therapy prior to
study entry. Best ORR was 23.7% (Table 3).[27] The DOR
was 7.8 months and median OS was 15.6 months. Subset
analyses by number and type of prior therapies and by
favourable vs unfavourable cytogenetic profile indicated
similar rates of response. The most common AEs were
fatigue (48.9%), anaemia (45.9%), nausea (44.7%) and
thrombocytopenia (38.7%) (Table 4). There was no evi-
dence of cumulative toxicities. New-onset PN was infre-
quent during the study, and only 2 patients experienced
Grade 3 or higher neuropathy.
PX-171-004 was a phase 2, open-label, multicenter clini-
cal trial that enrolled patients with RRMM following one to
three prior therapies (Table 3). The cohort of patients who
had received prior bortezomib (n = 35) received carfilzomib
20 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 every 28 days for
up to 12 cycles.[28] The ORR was 17.1% (Table 3). The
median DOR was >10.6 months and the median time to
progression was 4.6 months. More than 25% of patients
completed 12 cycles of treatment. The most common AEs
were fatigue (62.9%), nausea (60.0%) and vomiting
(42.9%). No exacerbation of baseline PN was observed, and
there were no dose reductions or discontinuations due to
PN.[28] The 129 bortezomib-naïve patients were separated
into cohort 1 (carfilzomib 20 mg/m2 for all cycles) and
cohort 2 (carfilzomib 20 mg/m2 for cycle 1 and 27 mg/m2
for all subsequent cycles). ORR was 42.4% in cohort 1 and
52.2% in cohort 2. For cohort 1, median DOR was 13.1
months and median time to progression (TTP) was 8.3
months. Neither median DOR nor median TTP was
reached in cohort 2. More than 35% of patients completed a
full 12 cycles of treatment. The most common treatment-
emergent AEs were fatigue (62.0%) and nausea (48.8%),
and there was a low overall incidence of PN (17.1%; no
Grade 4).[29]
Because these phase 1 and 2 studies demonstrated effi-
cacy and acceptable tolerability, patients were eligible for
inclusion in an extension study (PX-171-010).[30] As of June
2012, 89 patients with MM had enrolled and patients had
received a median of 10.5 cycles of carfilzomib during the
extension study (a median of 22 cycles in previous
study + the extension study). There was no evidence of
unique or late-onset cumulative toxicity.
Combination studies in relapsed
multiple myeloma
An initial phase 1b/2 study (PX-171-006) evaluated a com-
bination of escalating doses of carfilzomib and lenalido-
mide with low-dose dexamethasone in patients with
RRMM.[24] The ranges for carfilzomib (IV infusion over
2-10 min) and lenalidomide were 15–27 mg/m2 (D1, 2, 8, 9,
15, 16) and 10–25 mg (D1–21), respectively, and the dexam-
ethasone dose was 40 mg (D1, 8, 15, 22), given in 28-day
Table 4 Adverse event profile across phase 2 studies analysed in an integrated safety anaylsis[31]
Adverse event
003-A0
(n = 46)
003-A1
(n = 266)
004
(n = 164)
005
(n = 50)
Total
(n = 526)
Adverse events of all grades occurring in 25% of patients
Patients with 1 AE 46 (100.0) 266 (100.0) 164 (100.0) 47 (94.0) 523 (99.4)
Fatigue 32 (69.6) 130 (48.9) 102 (62.2) 28 (56.0) 292 (55.5)
Anaemia 34 (73.9) 122 (45.9) 65 (39.6) 25 (50.0) 246 (46.8)
Nausea 16 (34.8) 119 (44.7) 83 (50.6) 18 (36.0) 236 (44.9)
Thrombocytopenia 23 (50.0) 103 (38.7) 50 (30.5) 15 (30.0) 191 (36.3)
Dyspnoea 13 (28.3) 90 (33.8) 65 (39.6) 14 (28.0) 182 (34.6)
Diarrhoea 15 (32.6) 86 (32.3) 53 (32.3) 18 (36.0) 172 (32.7)
Pyrexia 15 (32.6) 83 (31.2) 51 (31.1) 11 (22.0) 160 (30.4)
Upper respiratory tract infection 17 (37.0) 71 (26.7) 52 (31.7) 9 (18.0) 149 (28.3)
Headache 12 (26.1) 74 (27.8) 51 (31.1) 8 (16.0) 145 (27.6)
Cough 13 (28.3) 65 (24.4) 51 (31.1) 8 (16.0) 137 (26.0)
Adverse events of Grade 3/4 occurring in 10% of patients
Patients with 1 AE 39 (84.8) 231 (86.8) 107 (65.2) 45 (90.0) 422 (80.2)
Thrombocytopenia 12 (26.1) 77 (28.9) 24 (14.6) 10 (20.0) 123 (23.4)
Anaemia 17 (37.0) 63 (23.7) 24 (14.6) 14 (28.0) 118 (22.4)
Lymphopenia 13 (28.3) 52 (19.5) 21 (12.8) 9 (18.0) 95 (18.1)
Pneumoniaa 5 (10.9) 25 (9.4) 19 (11.6) 6 (12.0) 55 (10.5)
Neutropenia 2 (4.3) 29 (10.9) 20 (12.2) 3 (6.0) 54 (10.3)
aOne Grade 5 event of pneumonia in 003-A1.
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cycles. MTD was not reached, and the combination of the
highest doses tested was well tolerated. Most AEs were
reversible and manageable, and prolonged administration
did not uncover any new or overlapping toxicities. AEs 
Grade 3 were mainly haematologic. Responses  very good
partial response (VGPR) were seen at all dose levels, and
ORR was 78% at the highest dose level.[24]
Adverse events
General safety and tolerability
Across all phase 2 studies, the majority of patients experi-
enced at least one treatment-emergent AE during treatment
(Table 4).[31] The most common AEs of any grade were
fatigue, anaemia and nausea. The most common Grade 3
AEs were primarily haematologic and included thrombocy-
topenia (23.4%), anaemia (22.4%), lymphopenia (18.1%)
and pneumonia (10.5%). SAEs were reported in 45% of
patients.[9] The most common SAEs regardless of causality
across phase 2 studies were pneumonia, acute renal failure,
pyrexia, congestive heart failure, dyspnoea, hypercalcemia
and pathologic fracture. AEs resulting in discontinuation of
therapy occurred in 15% of patients.[9]
Warnings and precautions for use
First-dose effects, infusion reactions and tumour
lysis syndrome
Symptoms including fever, chills, arthralgia and other
related reactions have occurred during and up to 24 h fol-
lowing infusion. In a phase 1 study, at a dose of 27 mg/m2, 3
of 5 patients had a reversible Grade 2 increase in creatinine
associated with a rapid decline in M-protein without evi-
dence of tumour lysis syndrome (TLS) noted on day 2 of
treatment.[23] In phase 2 studies, the escalated regimen was
used, along with premedication with dexamethasone to
mitigate possible infusion-related reactions,[27,29] and this
approach is recommended in the prescribing information.[9]
Carfilzomib has been associated with TLS in <1% of
patients across phase 2 clinical trials;[9] but patients with
relapsed MM and high tumour burden may be at higher
risk. These patients should be well-hydrated and monitored
closely for signs or symptoms of emerging TLS.[9] Other
TLS prophylaxis strategies should also be implemented as
indicated.
Haematologic events
Haematologic events comprise the majority of Grade 3/4
AEs occurring in >10% of patients (see Table 4). Complete
blood counts should be monitored regularly during therapy.
Specific recommendations for holding or reducing doses
are included in the prescribing information.[9] Thrombocy-
topenia in phase 2 studies was transient and cyclic, with
platelet counts predictably decreasing to a nadir by day 8
of the 28-day cycle and returning to normal by the first day
of the subsequent cycle.[31] There has been no evidence of
cumulative thrombocytopenia or clinically significant
bleeding associated with thrombocytopenia. Febrile neutro-
penia was reported in only 1% of patients. Across the
studies, dose reductions and discontinuations due to hae-
matologic AEs were 1.1%.[32]
Peripheral neuropathy (PN)
A relatively low incidence of PN was reported (13.9%
overall) across all phase 2 studies.[31] Of 526 patients only
1.3% had Grade 3 PN, and no  Grade 4 PN was reported.
Despite a large proportion (71.9%) of patients with active
PN (Grade 1 or 2) at study entry, the majority (87.3%) did
not report AEs of PN during treatment or within 30 days of
the last dose of carfilzomib. Discontinuations and dose
modifications in response to PN-related AEs were rare
(0.2% and 0.8%, respectively).[33]
Renal events
Hydration is recommended to reduce the potential risk of
renal AEs from carfilzomib treatment, particularly in cycle
1.[9] In the clinical trials to date, the majority of patients
(63.1%) had some degree of renal dysfunction at the time
of study entry.[31,34] The majority of renal AEs were Grade 1
or 2.[9] Transient worsening of renal function (defined as
2¥ increase in serum creatinine with a return to baseline)
was reported in 6% of patients. Non-transient worsening of
renal function was reported in 7% of patients. Thirty-eight
patients (7%) experienced Grade 3/4 acute renal AEs, of
which 31 were Grade 3. Overall, 1.5% of all patients discon-
tinued treatment due to renal AEs, and 50% of patients
with acute renal failure AEs required no change in carfil-
zomib therapy.[34] Additionally, a carfilzomib study involv-
ing patients with R/R MM demonstrated no difference in
grade or frequency of AEs across groups with varying
degrees of renal dysfunction.[22]
Cardiac and pulmonary events
Cardiac failure events (including congestive heart failure,
pulmonary oedema and decreased ejection fraction) were
reported in 7% of patients regardless of causality, and death
due to cardiac arrest in patients with a history of cardiac
conditions has occurred during carfilzomib treatment.[9]
Cardiac events resulting in treatment discontinuation
occurred in 23 patients (4.4%) and included congestive
heart failure (1.7%), arrhythmia (1.1%) and ischemic heart
disease (1.0%).[35] Patients should be closely monitored for
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new or worsening cardiac symptoms. Patients with existing
significant cardiac history were excluded from clinical trials
and may be at higher risk.[9]
Dyspnoea (grouped by multiple dyspnea terms) occurred
in 42.2% of patients.[35] The majority of the dyspnoea events
were Grade 1 or 2, with 4.8% of patients reporting Grade 3
and one death occurring in the clinical setting of congestive
heart failure. Patients who develop dyspnoea during treat-
ment should not receive further doses until symptoms have
resolved or returned to baseline.[9]
Carcinogenicity/mutagenicity and
reproductive effects
Formal carcinogenicity or teratogenicity studies have not
been conducted in humans, although carfilzomib has
caused embryo-foetal toxicity in animal studies.[9] There
have been no adequate or well-controlled studies of carfil-
zomib in pregnant or nursing mothers.
Preparation and administration
Carfilzomib for Injection (Kyprolis®, Onyx Pharmaceuti-
cals, South San Francisco, CA) is supplied as a lyophilized
powder in 60-mg single-use vials. Prior to administration,
the lyophilized product is reconstituted with sterile water
for injection to yield a 2 mg/ml solution[29] of carfilzomib.
Lyophilized carfilzomib should be stored in a refrigerator
(2–8°C); transient temperature excursion data are not avail-
able. Reconstituted solution is stable for 24 h refrigerated or
4 h at ambient room temperature. Prepared doses should be
used immediately.
Per prescribing information, carfilzomib should be
administered via IV infusion over 2–10 min and can be
given without further dilution (as 2 mg/ml solution) or
further diluted in 50 ml of 5% dextrose solution. Carfil-
zomib has also been administered IV over 30 min in some
clinical trials.[25,36] Longer or alternative administration
techniques may improve safety and tolerability. Carfilzomib
may be administered via either central or peripheral access.
There is no compatibility information available with other
parenteral drugs, so patients should have a dedicated line or
port for drug administration, and the line should be flushed
before and after administration with either 0.9% NaCl or
5% dextrose solution.[9] Carfilzomib is not considered a
vesicant, but the infusion site should be evaluated for local
reactions.
Dosing
Carfilzomib is dosed based on body surface area (BSA),
which should be capped at 2.2 m2. Actual body weight and
the same formula should be used to calculate BSA through-
out dosing.
The approved dosing schedule for carfilzomib is on days
1, 2, 8, 9, 15 and 16 of a 28-day cycle, at a dose of 20 mg/m2
in cycle 1, escalating to 27 mg/m2 in cycle 2 and thereafter.
Premedication with dexamethasone is recommended for all
doses in cycle 1 and the first doses of cycle 2 to reduce the
incidence and severity of possible acute reactions. Adequate
hydration beginning in cycle 1 and continuing throughout
treatment is recommended to reduce the risk of renal toxic-
ity and TLS. Alternative dosing strategies (described above)
are being investigated, and these may allow escalation to
doses of up to 56 mg/m2 or higher.[25]
Future directions
Table 5 lists ongoing studies for single-agent and combina-
tion carfilzomib therapy. Combination regimens that
include a PI are among the current NCCN category 1 rec-
ommendations for MM treatment and form the basis for
exploring carfilzomib as part of novel combinations, with a
goal of improving clinical responses without the need to
manage overlapping or DLTs.[37] Immunomodulatory drugs
sensitize MM to PI inhibitors, which may improve clinical
activity in combination.[38] In addition, pharmacogenomic
modelling studies are underway to help identify those
patients most likely to benefit from PI therapy.[38] These
results may help to further clarify the optimal use of carfil-
zomib in treating patients with MM.
Initial (frontline) therapy
All current category 1 NCCN recommendations for newly
diagnosed patients involve at least two drug combina-
tions.[37] Based on these recommendations and on the safety
profile of carfilzomib, there are several phase 2 studies of
frontline combination therapy with carfilzomib (Table 5).
In the CRd trial, carfilzomib doses up to 36 mg/m2 were
given in an escalated approach, and results have shown the
three-drug combination to be well tolerated and highly
active in patients with both favourable and unfavourable
cytogenetics.[36] Overall, progression-free survival (PFS) at
24 months was estimated at 92%. Patients who were eligible
received autologous stem cell transplantation (ASCT) or
went on to receive CRd and eventually lenalidomide alone
as maintenance therapy. These results are supported by a
similar study (NCT01402284) in which CRd followed by
lenalidomide maintenance and delayed ASCT was effective
and tolerable.[39]
The CARTHADEX (CTd) trial is evaluating carfilzomib
in combination with thalidomide and dexamethasone in
frontline induction and consolidation prior to ASCT, and
analysis of the first cohort shows the combination is a
rapidly effective induction regimen.[40] Preliminary results
of the four-drug regimen being evaluated in the CYCLONE
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(CCyTd) trial have shown a 96% response rate after four
cycles, with manageable toxicities.[41]
A trial of carfilzomib, melphalan and prednisone (CMP)
for frontline treatment in the elderly is currently underway.
Preliminary results have shown an ORR of 92%, which
compares favourably with other regimens evaluated in this
population.[42] Another study in elderly patients is investi-
gating carfilzomib, cyclophosphamide and dexamethasone;
the combination has been well-tolerated in this population,
and preliminary results show all response-evaluable patients
achieving at least a partial response.[43]
Taken as a whole, the preliminary results of these and
other frontline regimens show promise for combination
therapies using carfilzomib. Questions remain, including
the long-term tolerability and durability of clinical
response, the role of maintenance therapy, and the optimal
dose and regimen of each drug in the combination.
Maintenance therapy
Continued or maintenance therapy after ASCT has been
shown to reduce the risk of relapse, but the only current
NCCN category 1 recommendation is for lenalidomide as
monotherapy[37] and there are emerging safety concerns
with long-term lenalidomide therapy.[44] Based on promis-
ing results from the frontline CRd study,[36] there may be a
role for carfilzomib in combination in maintenance therapy,
with or without ASCT. The results of the CARTHADEX
trial show that when the carfilzomib combination is used as
consolidation, there is a significant upgrade of responses.[40]
Long-term use of carfilzomib, either as a single agent or
in combination, has been shown to be tolerable in an exten-
sion trial following previous use of carfilzomib. Dosing
either twice a week or in a reduced regimen of once a week
has been shown to be effective and tolerable.[30]
Salvage therapy
Studies are also in progress to evaluate carfilzomib in
combination regimens in the relapsed populations.
ENDEAVOR, a phase 3 trial comparing carfilzomib +
dexamethasone to bortezomib + dexamethasone in relapsed
patients, is underway (NCT01568866). The ASPIRE trial, a
phase 3 randomized controlled study comparing CRd to
lenalidomide + dexamethasone (Rd) in relapsed patients,
is also currently enrolling (NCT01080391). FOCUS
(NCT01302392) is a European registrational study evaluat-
ing single-agent carfilzomib in patients in comparison to a
best supportive care regimen.[45]
Other agents, including the histone deacetylase (HDAC)
inhibitors (panobinostat, vorinostat, tubacin) and the Akt
inhibitor perifosine, have shown in-vitro synergy and MM
cytotoxicity used in combination with PIs.[46,47] Combination
therapy with CRd + vorinostat has shown promise in
certain subpopulations of RRMM patients,[46] and recent
results from two dose-escalation studies combining carfil-
zomib and panobinostat show the combination to have a
manageable safety profile[48,49] and promising efficacy in very
heavily pre-treated patients.[48] The novel kinesin spindle
protein (KSP) inhibitor ARRY-520 has shown benefit in
RRMM treatment, and a phase 1 study, in progress, combin-
ing ARRY-520 and carfilzomib, reports the combination to
have limited haematologic toxicity and a manageable side-
effect profile with early signs of efficacy.[50] A phase 1/2 study
is also underway combining various doses of carfilzomib
given in an escalated regimen with pegylated liposomal
doxorubicin (NCT01246063). In addition, two studies are
underway to determine safety, MTD and efficacy of carfil-
zomib in combination with pomalidomide and dexa-
methasone in patients with relapsed/refractory disease
(NCT01464034 and NCT01665794), and early reports indi-
cate the combination is well tolerated and achieves high
response rates in heavily pre-treated patients.[51]
As with the frontline regimens, additional studies,
including a phase 3 trial, will likely be necessary to answer
questions regarding long-term durability of response, the
role of carfilzomib combination regimens in maintenance
therapy, and the optimal dose and regimen of drugs in the
combination.
Optimal dosing strategies
Although an MTD of 56 mg/m2 was defined in patients
with RRMM in the PX-171-007 study, doses up to
70 mg/m2 have been administered, with increased PD
response.[25] It is possible that alternative dosing regimens
(e.g. once weekly dosing) may prove to be well tolerated
with improved outcomes.[30] Carfilzomib monotherapy in
patients with RRMM has been well-tolerated when given as
a 30-min infusion in escalated regimens up to 56 mg/
m2.[25,52] Combining this regimen with low-dose dexametha-
sone appears to decrease some carfilzomib-related AEs.[53]
Additionally, based on results from the frontline CRd study,
when used in combination, carfilzomib doses of 36 mg/m2
in an escalated fashion are well tolerated.[36] Several trials
will continue to evaluate similar or higher dosing regimens.
The Car-BiRd study (NCT01559935) will employ carfil-
zomib doses of 45 mg/m2, and the CCD study is evaluating
20/36 mg/m2 escalated dosing of carfilzomib in com-
bination with cyclophosphamide and dexamethasone
(NCT01346787).
Other malignancies and diseases
Additional in-vitro and phase 1 studies of carfilzomib have
suggested the potential for activity in other haematologic
malignancies, including diffuse large B-cell lymphoma,
Hodgkin’s lymphoma, Waldenström’s macroglobulinemia,
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mantle-cell lymphoma and chronic lymphocytic leuke-
mia.[17,21,23,54,55] Based on responses seen with bortezomib,
carfilzomib may also have a role in organ transplantation
and graft vs host disease.[56] In these settings, carfilzomib
offers the potential advantage of higher doses or longer
durations of therapy due to the lower incidence of dose-
limiting PN relative to that seen with bortezomib.
Conclusions
Carfilzomib is an important new addition to the array of
drugs available to treat patients with RRMM. It has shown
rapid, durable responses and an acceptable tolerability
profile in heavily pre-treated patients. There has been no
evidence of cumulative or significant treatment-limiting
toxicity, despite prior treatment with bortezomib and
immunomodulatory drugs in the majority of patients.
Additionally, carfilzomib has demonstrated potential for
long-term use without the need for dose adjustment or
interruption. Management measures exist to mitigate the
risk for AEs, even in patients with advanced disease or oth-
erwise considered to be at high risk. While questions remain
regarding optimal dosing strategies, either alone or in com-
bination, and utility in other populations and diseases, car-
filzomib fills an unmet need in the treatment of RRMM, as
it offers an important treatment option for patients who
have either failed or cannot tolerate other treatments. In
addition, carfilzomib shows promise in frontline MM treat-
ment, as well as other malignancies.
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